OBJECTIVE： To investigate clinical efficacy and safety of linezolid in the treatment of intracranial infection after neurosurgery operation. METHODS： Medical information of 39 intracranial infection patients receiving linezolid in Xijing Hospital of Air Force Medical University during Jul. 1st， 2015-Aug. 29th， 2016 were analyzed retrospectively. The clinical efficacy and safety of linezolid in the treatment of intracranial infection after neurosurgery operation were evaluated according to indexes of intracranial infection patient， such as symptoms， signs， lab indexes test and bacterial culture results. RESULTS： Total response rate of 39 intracranial infection patients after neurosurgery operation was 79.49％ after linezolid treatment. After treatment，the patients’body temperature， white blood cell， neutrophil absolute value， white blood cell in cerebrospinal fluid and cerebrospinal fluid protein level were all significantly lower than before treatment， with statistical significance（P＜0.05）. Of 39 patients， cerebrospinal fluid of 27 patients were cultured before treatment， and 8 cases （29.6％） of which were positive， among which there were 6 cases （75.0％） of Gram-positive bacteria such as Staphylococcus and Enterococcus. No obvious ADR related to linezolid was found in patients. CONCLUSIONS： Linezolid can effectively control the intracranial infection caused by Gram-positive bacteria such as Staphylococcus and Enterococcus with good safety.